Sun Pharma Secures Relief Against Phonetic Similarity in Pharmaceutical Trademarks "Octride" and "Otide"
In a significant ruling, the Bombay High Court has granted an interim injunction in favor of Sun Pharma Laboratories Limited, preventing United Biotech Private Limited from using the trademarks "Octide" and "Otide" in relation to their pharmaceutical products. The judgment, delivered by Justice Sharmila U. Deshmukh, addresses the contentious issue of trademark infringement and passing off within the pharmaceutical industry.
The court recognized the phonetic similarity between Sun Pharma's registered trademark "Octride" and United Biotech's "Otide," emphasizing the potential confusion such similarity might cause, particularly in the context of medicinal products. Sun Pharma demonstrated its established goodwill and reputation for the trademark "Octride," which has been in use since 1999, contrasting United Biotech's use of "Otide" which began in 2006.
The court noted that both trademarks are derived from the active pharmaceutical ingredient Octreotide Acetate, used to treat serious medical conditions such as acromegaly and carcinoid tumors. Despite United Biotech's registration of the "Otide" trademark, the court found that the phonetic similarity could lead to public confusion, especially given the hurried nature of medical prescriptions and the potential harm from such confusion.
Justice Deshmukh underscored the need for exacting judicial scrutiny for pharmaceutical trademarks due to their implications on public health. The court held that the balance of convenience favored Sun Pharma, given its higher sales turnover and established reputation, granting interim relief to protect its goodwill.
United Biotech's plea of acquiescence was rejected, as the court differentiated between mere delay and positive acquiescence. The judgment emphasized that Sun Pharma's knowledge of United Biotech's trademark did not equate to acquiescence, as no damage was demonstrated during the period of inactivity.
The decision aligns with precedents set by the Supreme Court in similar cases, reinforcing the principle that phonetic similarity in pharmaceutical trademarks necessitates judicial intervention to prevent public health risks and protect established goodwill.
Bottom line:-
Trademark infringement and passing off - Case involving pharmaceutical trademarks "Octride" and "Otide" - Interim injunction granted to prevent passing off due to phonetic similarity and potential confusion in medicinal products.
Statutory provision(s): Trade Marks Act, 1999 Sections 27(2), 28(3), 30(2)(e), 31, 55
